{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["napabucasin"]],"indication":"previously untreated metastatic pancreatic adenocarcinoma","name":"CanStem111P","nct_id":"NCT02993731","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=canstem111p-nct02993731. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"CanStem111P","arms":[{"description":"Patients randomized to this arm will receive napabucasin administered orally, twice daily in combination with weekly nab-paclitaxel and gemcitabine administered intravenously, once weekly, on 3 of every 4 weeks.","label":"Arm 1: Napabucasin plus Nab-paclitaxel with Gemcitabine","type":"EXPERIMENTAL"},{"description":"Patients randomized to this arm will receive weekly nab-paclitaxel and gemcitabine administered intravenously, once weekly, on 3 of every 4 weeks.","label":"Arm 2: Nab-paclitaxel with Gemcitabine","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2020-03","type":"ACTUAL"},"conditions":["Carcinoma, Pancreatic Ductal"],"enrollment":{"count":1134,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Napabucasin","otherNames":["BBI-608","BBI608","BB608"],"type":"DRUG"},{"name":"Nab-paclitaxel","otherNames":["Abraxane"],"type":"DRUG"},{"name":"Gemcitabine","otherNames":["Gemzar"],"type":"DRUG"}],"last_update":"2023-11-15","lead_sponsor":"Sumitomo Pharma America, Inc.","official_title":"A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2020-03","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival","timeFrame":"From 4 weeks after the patient has been off study therapy, every 4 weeks thereafter for 6 months, then every 3 months thereafter until death, the study closes or 3 years since treatment discontinuation."}],"references":[],"start_date":{"date":"2016-12"},"study_type":"INTERVENTIONAL","title":"A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma","url":"https://clinicaltrials.gov/study/NCT02993731"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/canstem111p-nct02993731"}